Prospective study reveals glymphatic dysfunction in brain tumor patients, indicating possible treatment pathways.
Brain tumors disrupt the glymphatic system-a critical network for cerebrospinal and interstitial fluid circulation via the perivascular spaces (PVS)-yet the extent and underlying mechanisms of this dysfunction remain poorly defined. In a prospective study, 104 brain tumor patients (40 high-grade gliomas, 26 metastases, and 38 meningiomas) and 30 age- and sex-matched healthy controls underwent advanced MRI assessments to quantify white matter PVS volume fraction (PVSVF-WM), free water fraction (FW-WM), and the DTI-ALPS index. All tumor groups exhibited significantly elevated PVSVF-WM (p < .001) and reduced DTI-ALPS index, indicating PVS dilation and impaired glymphatic function, while FW-WM showed significant group differences, with the lowest values observed in patients with high-grade glioma (p < .001). Tumor volume showed a strong positive correlation with PVSVF-WM (ρ = 0.674, p < .001) and a negative correlation with the DTI-ALPS index (ρ = -0.482, p < .001). Moreover, in gliomas, Ki67 expression correlated positively with PVSVF-WM (ρ = 0.563, p < .001) and negatively with the DTI-ALPS index (ρ = -0.482, p = .002), whereas in metastases, p53 expression correlated positively with the DTI-ALPS index (ρ = 0.569, p = .002). These findings demonstrate that brain tumors alter the PVS network, leading to glymphatic dysfunction, with the degree of disruption being modulated by tumor burden and molecular characteristics. The innovative MRI-based metrics used in this study provide valuable insights into tumor-associated glymphatic alterations and may inform the development of tailored therapeutic interventions.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: